Investigating the Incretin Effect in Cystic Fibrosis

Launched by LIVERPOOL HEART AND CHEST HOSPITAL NHS FOUNDATION TRUST · Oct 28, 2013

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Cystic fibrosis as diagnosed by EITHER Cystic fibrosis transmembrane conductance regulator (CFTR) mutation on genotyping OR Positive sweat test (Chloride ≥60mmol/L after pilocarpine iontophoresis) AND Clinical features in keeping with a diagnosis of Cystic Fibrosis
• • Clinically stable for at least 4 weeks without inpatient or outpatient treatment for an infective exacerbation - including antibiotics (other than long-term prophylactic therapy) or steroids
• Exclusion Criteria:
• • Active Pregnancy or \<12 months Post-partum
• • Clinically unstable patients
• • Patients on long-term steroids
• • Patients with known gastroparesis or previous surgery to the gastrointestinal tract (including vagotomy)
• • History of organ transplant or planned organ transplant awaited
• • Non-CF related diabetes (e.g. Type 1 or 2 Diabetes Mellitus)
• • Active malignancy
• • Clinically significant derangements in haematological or biochemical indices
• • Clinical symptoms of malabsorption (frequent bowel motions/passing of undigested foodstuffs or steatorrhoea)
• • Known difficult venous access
• • Use of bile acid sequestrants in the previous 4 weeks